Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-three cents ($0.63) per share on the $0.10 par value common stock of the...
/Bristol-Myers%20Squibb%20Co_%20logo%20on%20building-by%20tatu%20Campelo%20via%20iStock.jpg)
Though Bristol-Myers Squibb has lagged behind the broader Nasdaq Composite over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.
Izalontamab brengitecan (Iza-bren) met its dual primary endpoints of progression free survival (“PFS”) and overall survival (“OS”) in an interim analysis of a Phase 3 trial (NCT06382142) conducted...
EQNX::TICKER_START (NASDAQ:HELP),(CBOE:HELP),(NYSE:TAK),(NASDAQ:CMPS),(NYSE:PFE),(NYSE:BMY) EQNX::TICKER_END
Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in the TD Cowen 46 th Annual Health Care Conference on Monday, March 2, 2026. The...
Both non-transfusion-dependent and transfusion dependent cohorts met their respective primary and secondary endpoints
2 Large-Cap Stocks on Our Buy List and 1 That Underwhelm
Iberdomide has the potential to be the first approved CELMoD agent The U.S. FDA has granted Breakthrough Therapy Designation and Priority Review for this indication and...
The 5 Most Interesting Analyst Questions From Bristol-Myers Squibb’s Q4 Earnings Call